12:00 AM
Nov 19, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

PF-4950615: Phase I data

A double-blind, U.S. Phase I trial in 67 diet-managed patients with hypercholesterolemia, including 9 of Japanese ancestry, showed that RN316 was generally well tolerated with infrequent and transient adverse events that were not dose-related reported. One patient reported non-serious infusion reactions on...

Read the full 189 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >